November 17th, 2026From Keytruda biosimilar to novel ADC: Samsung Bioepis’ 2-track oncology strategySBE303, a Nectin-4 ADC for previously treated bladder cancer, is in phase 1 as the company advances SB27, its proposed Keytruda biosimilar.Read more